SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years clinical trials

A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

This study is testing a new cancer vaccine called SurVaxM for children and young adults with specific types of brain tumours. It aims to train the body's immune system to find and destroy cancer cells that have a special protein.